Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors
暂无分享,去创建一个
Armin Ruf | Jörg Benz | Bernd Kuhn | B. Kuhn | J. Benz | A. Ruf | M. Wright | U. Grether | P. Mohr | P. Hartman | H. Maerki | Matthew B Wright | Uwe Grether | Peter Hartman | Peter Mohr | Michel Dietz | Hans Peter Maerki | Michel Dietz
[1] J. Girard,et al. Phosphorylation of PPARs: from molecular characterization to physiological relevance. , 2005, Biochimie.
[2] B. Kuhn,et al. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. , 2009, Bioorganic & medicinal chemistry letters.
[3] A. Depaoli,et al. Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. , 2011, Journal of diabetes and its complications.
[4] K. Moulder,et al. Sulfated Glycans Stimulate Endocytosis of the Cellular Isoform of the Prion Protein, PrPC, in Cultured Cells (*) , 1995, The Journal of Biological Chemistry.
[5] Armin Ruf,et al. Design and Biological Evaluation of Novel, Balanced Dual PPARα/γ Agonists , 2009, ChemMedChem.
[6] R. Buckingham,et al. Thiazolidinediones and their Fluid-Related Adverse Effects , 2007, Drug safety.
[7] T. Saheki,et al. Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice , 2002, Nature Genetics.
[8] Sukjoon Yoon,et al. 1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists. , 2010, Bioorganic & medicinal chemistry.
[9] J. Auwerx,et al. SRC-1 and TIF2 Control Energy Balance between White and Brown Adipose Tissues , 2002, Cell.
[10] J. Lehmann,et al. An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.
[11] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.
[12] J. Auwerx,et al. Peroxisome proliferator‐activated receptor‐γ: too much of a good thing causes harm , 2004 .
[13] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[14] A. Scheen. Hepatotoxicity with Thiazolidinediones , 2001, Drug safety.
[15] R. DeFronzo,et al. Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual (α/γ) Peroxisome Proliferator–Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy , 2006, Diabetes Care.
[16] J. V. Vanden Heuvel,et al. Modulation of PPAR activity via phosphorylation. , 2007, Biochimica et biophysica acta.
[17] P. Meinke,et al. Nuclear Hormone Receptor Modulators for the Treatment of Diabetes and Dyslipidemia , 2006 .
[18] G. Schroth,et al. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR γ agonists on rat primary hepatocytes and human HepG2 cells , 2006, Molecular Diversity.
[19] C. Glass,et al. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. , 1998, Genes & development.
[20] E. Tuzcu,et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.
[21] M. Lindstrom,et al. INT131: A Selective Modulator of PPARγ , 2009 .
[22] Richard Barnett. Diabetes , 1904, The Lancet.
[23] D. Grobbee,et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis , 2010, The Lancet.
[24] A. Kelly,et al. The cardiovascular effects of the thiazolidinediones: a review of the clinical data. , 2007, Journal of diabetes and its complications.
[25] R. Ratner,et al. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes , 2007, Diabetes & vascular disease research.
[26] P. Renard,et al. S 26948 , 2007, Diabetes.
[27] E. Topol,et al. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. , 2005, JAMA.
[28] B. Kuhn,et al. New Insights on the Mechanism of PPAR‐targeted Drugs , 2010, ChemMedChem.
[29] R.R. Patel. Thiazolidinediones and Congestive Heart Failure: A Judicious Balance of Risks and Benefits , 2009, Cardiology in review.
[30] Warszawski Uniwersytet Medyczny,et al. Diabetes care , 2019, Health at a Glance.
[31] Millard H. Lambert,et al. Asymmetry in the PPARγ/RXRα Crystal Structure Reveals the Molecular Basis of Heterodimerization among Nuclear Receptors , 2000 .
[32] R. Heyman,et al. Three amino acids specify coactivator choice by retinoid X receptors. , 2000, Molecular endocrinology.
[33] R. Rosenfeld. Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[34] S. Mudaliar,et al. Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study , 2009, The Lancet.
[35] W. Alexander,et al. American diabetes association. , 2010, P & T : a peer-reviewed journal for formulary management.
[36] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[37] J. Auwerx,et al. PPAR(gamma) and glucose homeostasis. , 2003, Annual review of nutrition.
[38] H. Bays,et al. A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus , 2007, Diabetes & vascular disease research.
[39] Arya M. Sharma,et al. Can PPARgamma agonists have a role in the management of obesity-related hypertension? , 2006, Vascular pharmacology.
[40] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[41] B. Staels,et al. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis , 2006, Expert opinion on emerging drugs.
[42] M. Lambert,et al. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. , 2007, Journal of medicinal chemistry.
[43] J. Auwerx,et al. Peroxisome proliferator-activated receptor γ, the ultimate liaison between fat and transcription , 2000 .
[44] C. Sigmund,et al. Peroxisome Proliferator-Activated Receptor-β and its Agonists in Hypertension and Atherosclerosis , 2005 .
[45] Nancy Claude,et al. Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes , 2011, PloS one.
[46] S. Kato,et al. Ligand type-specific Interactions of Peroxisome Proliferator-activated Receptor γ with Transcriptional Coactivators* , 2000, The Journal of Biological Chemistry.
[47] J. Leers,et al. Mechanistic Principles in NR Box-Dependent Interaction between Nuclear Hormone Receptors and the Coactivator TIF2 , 1998, Molecular and Cellular Biology.
[48] C. Glass,et al. Anti-inflammatory and antidiabetic roles of PPARgamma. , 2007, Novartis Foundation symposium.
[49] B. Spiegelman. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. , 1998, Diabetes.
[50] S. Haffner,et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.
[51] B. Spiegelman,et al. Transcription coactivator TRAP220 is required for PPARγ2-stimulated adipogenesis , 2002, Nature.
[52] B. Zinman,et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.
[53] Patrick R. Griffin,et al. Obesity-linked phosphorylation of PPARγ by cdk5 is a direct target of the anti-diabetic PPARγ ligands , 2010, Nature.